IP Verse

Method For Purification Of Alpha-1-Antitrypsin - EP3006462

EP3006462

CSL BEHRING
Application Number
EP15193455A
Filing Date
Dec 19, 2003
Status
Revoked
Mar 29, 2024
Grant Date
Apr 10, 2019
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3006462B1 was granted to CSL Behring on Apr 10, 2019 following the initial filing on Dec 19, 2003 under the application number EP15193455A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEEMINGJan 10, 2020ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
DESCRIPTIONEP0067293
DESCRIPTIONEP0224811
DESCRIPTIONEP0282363
DESCRIPTIONEP0717049
DESCRIPTIONJPH0899999
DESCRIPTIONJPS59128335
DESCRIPTIONUS2002082214
DESCRIPTIONUS3293236
DESCRIPTIONUS3301842
DESCRIPTIONUS4379087
DESCRIPTIONUS4439358
DESCRIPTIONUS4629567
DESCRIPTIONUS4656254
DESCRIPTIONUS4684723
DESCRIPTIONUS4697003
DESCRIPTIONUS4749783
DESCRIPTIONUS4820805
DESCRIPTIONUS4857317
DESCRIPTIONUS4876241
DESCRIPTIONUS5114863
DESCRIPTIONUS5610285
DESCRIPTIONUS5780014
DESCRIPTIONUS6093804
DESCRIPTIONUS6096216
DESCRIPTIONUS6106773
DESCRIPTIONUS6138668
DESCRIPTIONUS6187572
DESCRIPTIONUS6369048
DESCRIPTIONUS6436344
DESCRIPTIONUS6465168
DESCRIPTIONWO9524428
DESCRIPTIONWO9535306
DESCRIPTIONWO9856821
OPPOSITIONEP0698615
OPPOSITIONEP2295126
OPPOSITIONWO0248176
OPPOSITIONWO9535306
SEARCHUS2002082214
SEARCHUS5616693

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- A.L. ARCHIBALD, PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 5178 - 5182-
DESCRIPTION- BRANTLY ET AL., AM. J. MED., (1988), vol. 84, no. 6A, pages 13 - 31-
DESCRIPTION- CRYSTAL ET AL., AM. J. RESPIR. CRIT. CARE MED., (1998), vol. 158, pages 49 - 59-
DESCRIPTION- D. LOMAS ET AL., EUR. RESP. J., (1997), vol. 10, pages 672 - 675-
DESCRIPTION- DUBIN ET AL., PREPARATIVE BIOCHEMISTRY, (1990), vol. 20, pages 63 - 70-
DESCRIPTION- E. J. COHN ET AL., J. AMER. CHEM. SOC., (1946), vol. 68, pages 459 - 475-
DESCRIPTION- GLASER ET AL., ANAL. BIOCHEM., (1982), vol. 124, pages 364 - 371-
DESCRIPTION- GLASER ET AL., PREPARATIVE BIOCHEMISTRY, (1975), vol. 5, pages 333 - 348-
DESCRIPTION- G. WRIGHT ET AL., BIOTECHNOLOGY, (1991), vol. 9, pages 830 - 834-
DESCRIPTION- J. HUANG ET AL., BIOTECHNOL. PROG., (2001), vol. 17, pages 126 - 133-
DESCRIPTION- J.T. WHICHER ET AL., CLIN. CHEM., (1994), vol. 40, pages 934 - 938-
DESCRIPTION- K. KWON ET AL., J. BIOTECHNOLOGY, (1995), vol. 42, pages 191 - 195-
DESCRIPTION- KRESS ET AL., PREPARATIVE BIOCHEMISTRY, (1973), vol. 3, pages 541 - 552-
DESCRIPTION- L. GAIDULIS ET AL., CLIN. CHEM., (1983), vol. 29, page 1838-
DESCRIPTION- MATTES ET AL., VOX SANGUINIS, (2001), vol. 81, pages 29 - 36-
DESCRIPTION- M.E. SVOBODA; J.J. VAN WYK, METH. ENZYMOLOGY,, (1985), vol. 109, pages 798 - 816-
DESCRIPTION- M. H. COAN, AMER. J. MED.,, (1988), vol. 84, no. 6A, pages 32 - 36-
DESCRIPTION- M. H. COAN ET AL., VOX SANG., (1985), vol. 48, pages 333 - 342-
DESCRIPTION- M. H. COAN ET AL., VOX SANG.,, (1985), vol. 48, pages 333 - 342-
DESCRIPTION- P. KISTLER; H. S. NITSCHMANN, VOX SANG., (1962), vol. 7, pages 414 - 424-
DESCRIPTION- PODIARENE ET AL., VOPR. MED. KHIM., (1989), vol. 35, pages 96 - 99-
DESCRIPTION- R. BISCHOFF ET AL., BIOCHEMISTRY, (1991), vol. 30, pages 3464 - 3472-
DESCRIPTION- R. H. HEIN ET AL., EUR. RESPIR. J., (1990), vol. 3, no. 9, pages 16S - 20S-
DESCRIPTION- R. MAHADEVA; D. LOMAS, THORAX, (1998), vol. 53, pages 501 - 505-
DESCRIPTION- R. PANNELL; D. JOHNSON; J. TRAVIS, BIOCHEMISTRY, (1974), vol. 13, pages 5439 - 5445-
DESCRIPTION- T. BURNOUF ET AL., VOX SANG., (1987), vol. 52, pages 291 - 297-
DESCRIPTION- W. STEPHAN, VOX SANGUINIS, (1971), vol. 20, pages 442 - 457-
EXAMINATION- GLASER C B ET AL, "The isolation of alpha-1-protease inhibitor by a unique procedure designed for industrial application", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 124, no. 2, doi:10.1016/0003-2697(82)90053-7, ISSN 0003-2697, (19820801), pages 364 - 371, (19820801), XP024825556
OPPOSITION- L. Gaidulis, Et Al, "Optimizing Reference Values for the Measurement of Alpha1-Antitrypsin in Serum: Comparison of Three Methods", Clin. Chem., (19830101), vol. 29, no. 10, pages 1838 - 1840, XP055672793-
OPPOSITION- POTEMPA J ET AL, "THE INACTIVATION OF HUMAN PLASMA ALPHA-1 PROTEINASE INHIBITOR BY PROTEINASES FROM STAPHYLOCOCCUS-AUREUS", JOURNAL OF BIOLOGICAL CHEMISTRY.(MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, US, (19860101), vol. 261, no. 30, pages 14330 - 14334, XP002154472-
OPPOSITION- Tech Tip #6, "Extinction Coefficients", Thermo Scientific, (20130101), pages 1 - 3, XP055672800-
OPPOSITION- Glaser C.B. et al, "The isolation of alpha-1-protease inhibitor by a unique procedure designed for industrial application", Analytical Biochemistry, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19820801), vol. 124, no. 2, doi:10.1016/0003-2697(82)90053-7, ISSN 0003-2697, pages 364 - 371, XP024825556
OPPOSITION- Ralph Pannell et al, "Isolation and Properties of Human Plasma a-1-Proteinase Inhibitor", Biochemistry, (19740101), vol. 13, no. 26, pages 5439 - 5445, XP055672782
OPPOSITION- MATTES E, ET AL, "Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity.", VOX SANGUINIS., CH, (20010701), vol. 81, no. 1, doi:10.1046/j.1423-0410.2001.00049.x, ISSN 0042-9007, pages 29 - 36, XP002448796
SEARCH- COWDEN D I ET AL, "A pilot study comparing the purity, functionality and isoform composition ofalpha-1-proteinase inhibitor (human) products", CURRENT MEDICAL RESEARCH AND OPINION, HANTS, GB, (20050101), vol. 21, no. 6, pages 877 - 883, XP008082922 [T] * the whole document *-
SEARCH- LODISH H F ET AL, "The secretory pathway is normal in dithiothreitol-treated cells, but disulfide-bonded proteins are reduced and reversibly retained in the endoplasmic reticulum", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, (19930925), vol. 268, no. 27, ISSN 0021-9258, pages 20598 - 20605, XP002361974 [A] 1-28 * the whole document *-
SEARCH- CHEN S X ET AL, "Chromatographic purification of human alpha1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, (19980327), vol. 800, no. 2, doi:10.1016/S0021-9673(97)01119-9, ISSN 0021-9673, pages 207 - 218, XP004113596 [A] 1-28 * page 214, paragraph last; figure 3; table 2 *
SEARCH- MATTES E ET AL, "Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity", VOX SANGUINIS, S. KARGER AG, BASEL, CH, (20010701), vol. 81, no. 1, doi:10.1046/J.1423-0410.2001.00049.X, ISSN 0042-9007, pages 29 - 36, XP002448796 [X] 1,7 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents